

Jaap J Boelens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8250075/publications.pdf>

Version: 2024-02-01

337
papers

11,720
citations

22146

59
h-index

36025

97
g-index

352
all docs

352
docs citations

352
times ranked

11724
citing authors

#	ARTICLE	IF	CITATIONS
1	Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy. <i>Science</i> , 2013, 341, 1233-1238.	12.6	998
2	Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. <i>Lancet</i> , The, 2012, 379, 1301-1309.	13.7	324
3	Defective cytotoxic lymphocyte degranulation in syntaxin-11-deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. <i>Blood</i> , 2007, 110, 1906-1915.	1.4	272
4	Metachromatic leukodystrophy: Disease spectrum and approaches for treatment. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2015, 29, 261-273.	4.7	268
5	Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. <i>Blood</i> , 2015, 125, 2164-2172.	1.4	262
6	Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis. <i>Cell Reports</i> , 2018, 23, 3946-3959.e6.	6.4	245
7	Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. <i>Lancet Haematology</i> , the, 2015, 2, e194-e203.	4.6	228
8	How I treat adenovirus in hematopoietic stem cell transplant recipients. <i>Blood</i> , 2010, 116, 5476-5485.	1.4	201
9	Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. <i>Lancet Haematology</i> , the, 2016, 3, e526-e536.	4.6	197
10	Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. <i>Orphanet Journal of Rare Diseases</i> , 2011, 6, 55.	2.7	194
11	Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. <i>Blood</i> , 2019, 134, 2361-2368.	1.4	190
12	Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. <i>Bone Marrow Transplantation</i> , 2007, 40, 225-233.	2.4	186
13	Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. <i>Blood</i> , 2013, 121, 3981-3987.	1.4	183
14	Anakinra for flares of pyogenic arthritis in PAPA syndrome. <i>British Journal of Rheumatology</i> , 2005, 44, 406-408.	2.3	175
15	The Clinical Outcome of Hurler Syndrome after Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 485-498.	2.0	161
16	Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis. <i>Lancet Haematology</i> , the, 2017, 4, e183-e191.	4.6	154
17	Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome. <i>Blood</i> , 2014, 123, 126-132.	1.4	149
18	Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation. <i>Blood</i> , 2016, 128, 2734-2741.	1.4	144

#	ARTICLE	IF	CITATIONS
19	Hematopoietic Cell Transplantation for Mucopolysaccharidosis Patients Is Safe and Effective: Results after Implementation of International Guidelines. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1106-1109.	2.0	138
20	Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. <i>Brain</i> , 2015, 138, 2847-2858.	7.6	128
21	Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2319-2321.	0.7	119
22	Biomaterial-Associated Persistence of Staphylococcus epidermidis in Pericatheter Macrophages. <i>Journal of Infectious Diseases</i> , 2000, 181, 1337-1349.	4.0	115
23	Body Weight-Dependent Pharmacokinetics of Busulfan in Paediatric Haematopoietic Stem Cell Transplantation Patients. <i>Clinical Pharmacokinetics</i> , 2012, 51, 331-345.	3.5	115
24	Current International Perspectives on Hematopoietic Stem Cell Transplantation for Inherited Metabolic Disorders. <i>Pediatric Clinics of North America</i> , 2010, 57, 123-145.	1.8	111
25	Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. <i>Journal of Clinical Oncology</i> , 2019, 37, 367-374.	1.6	110
26	Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e226-e246.	2.0	110
27	Human Herpes Virus 6 Plasma DNA Positivity after Hematopoietic Stem Cell Transplantation in Children: an Important Risk Factor for Clinical Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 831-839.	2.0	109
28	Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2. <i>Blood</i> , 2010, 116, 2635-2643.	1.4	108
29	Haematopoietic stem cell transplantation for autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2017, 13, 244-256.	8.0	108
30	Association between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan before Hematologic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 231-241.	2.0	107
31	Risk Factor Analysis of Outcomes after Unrelated Cord Blood Transplantation in Patients with Hurler Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 618-625.	2.0	105
32	Strong Association between Respiratory Viral Infection Early after Hematopoietic Stem Cell Transplantation and the Development of Life-Threatening Acute and Chronic Alloimmune Lung Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 782-791.	2.0	100
33	Immune Reconstitution Kinetics as an Early Predictor for Mortality using Various Hematopoietic Stem Cell Sources in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 305-313.	2.0	99
34	Trends in haematopoietic cell transplantation for inborn errors of metabolism. <i>Journal of Inherited Metabolic Disease</i> , 2006, 29, 413-420.	3.6	98
35	Rabbit Anti-T Cell Globulin in Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 959-970.	2.0	94
36	Musculoskeletal manifestations of lysosomal storage disorders. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1659-1665.	0.9	93

#	ARTICLE	IF	CITATIONS
37	Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome. <i>Bone Marrow Transplantation</i> , 2006, 38, 17-21.	2.4	92
38	Different NK cell-activating receptors preferentially recruit Rab27a or Munc13-4 to perforin-containing granules for cytotoxicity. <i>Blood</i> , 2009, 114, 4117-4127.	1.4	90
39	Fludarabine and Exposure-Targeted Busulfan Compares Favorably with Busulfan/Cyclophosphamide-Based Regimens in Pediatric Hematopoietic Cell Transplantation: Maintaining Efficacy with Less Toxicity. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 345-353.	2.0	89
40	Hematopoietic stem cell transplantation for infantile osteopetrosis. <i>Blood</i> , 2015, 126, 270-276.	1.4	89
41	Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantation. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1643-1650.e9.	2.9	87
42	Intensive care unit mortality trends in children after hematopoietic stem cell transplantation: A meta-regression analysis*. <i>Critical Care Medicine</i> , 2008, 36, 2898-2904.	0.9	81
43	Glutathione S-transferase Polymorphisms Are Not Associated With Population Pharmacokinetic Parameters of Busulfan in Pediatric Patients. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 504-510.	2.0	79
44	Population Pharmacokinetic Modeling of Thymoglobulin® in Children Receiving Allogeneic-Hematopoietic Cell Transplantation: Towards Improved Survival Through Individualized Dosing. <i>Clinical Pharmacokinetics</i> , 2015, 54, 435-446.	3.5	79
45	Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1874-1882.	2.0	78
46	Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. <i>Bone Marrow Transplantation</i> , 2020, 55, 1093-1102.	2.4	78
47	Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 195-206.	2.0	76
48	Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome. <i>New England Journal of Medicine</i> , 2021, 385, 1929-1940.	27.0	75
49	Relationship between Mixed Donor-Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2178-2183.	2.0	74
50	Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. <i>Lancet Haematology</i> , 2017, 4, e325-e333.	4.6	72
51	Fcγ3 receptor antigen targeting potentiates cross-presentation by human blood and lymphoid tissue BDCA-3+ dendritic cells. <i>Blood</i> , 2012, 120, 5163-5172.	1.4	71
52	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
53	Highly Variable Plasma Concentrations of Voriconazole in Pediatric Hematopoietic Stem Cell Transplantation Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 235-240.	3.2	70
54	Once-Daily Intravenous Busulfan with Therapeutic Drug Monitoring Compared to Conventional Oral Busulfan Improves Survival and Engraftment in Children Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 88-98.	2.0	69

#	ARTICLE	IF	CITATIONS
55	Effect of Weight and Maturation on Busulfan Clearance in Infants and Small Children Undergoing Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1608-1614.	2.0	69
56	Human herpesvirus type 6 reactivation after haematopoietic stem cell transplantation. <i>Journal of Clinical Virology</i> , 2008, 43, 361-366.	3.1	68
57	Hematopoietic Stem Cell Transplantation in Inborn Errors of Metabolism. <i>Frontiers in Pediatrics</i> , 2019, 7, 433.	1.9	68
58	Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation. <i>Oncolmmunology</i> , 2013, 2, e26403.	4.6	67
59	Allogeneic hematopoietic SCT for alpha-mannosidosis: an analysis of 17 patients. <i>Bone Marrow Transplantation</i> , 2012, 47, 352-359.	2.4	65
60	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 642-649.	1.2	65
61	Biomarker profiling of steroid-resistant acute GVHD in patients after infusion of mesenchymal stromal cells. <i>Leukemia</i> , 2015, 29, 1839-1846.	7.2	64
62	Transplantation in inborn errors of metabolism: current considerations and future perspectives. <i>British Journal of Haematology</i> , 2014, 167, 293-303.	2.5	60
63	Hematopoietic stem cell transplantation for CD40 ligand deficiency: Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2238-2253.	2.9	60
64	Efficacy of hematopoietic cell transplantation in metachromatic leukodystrophy: the Dutch experience. <i>Blood</i> , 2016, 127, 3098-3101.	1.4	56
65	Hematopoietic cell transplantation does not prevent myelopathy in X-linked adrenoleukodystrophy: a retrospective study. <i>Journal of Inherited Metabolic Disease</i> , 2015, 38, 359-361.	3.6	54
66	Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 240.	2.7	54
67	Defects in neutrophil granule mobilization and bactericidal activity in familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) syndrome caused by STXBP2/Munc18-2 mutations. <i>Blood</i> , 2013, 122, 109-111.	1.4	49
68	Predictive Performance of a Busulfan Pharmacokinetic Model in Children and Young Adults. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 574-583.	2.0	48
69	Related and unrelated donor transplantation for β^2 -thalassemia major: results of an international survey. <i>Blood Advances</i> , 2019, 3, 2562-2570.	5.2	48
70	Strategies before, during, and after hematopoietic cell transplantation to improve T-cell immune reconstitution. <i>Blood</i> , 2016, 128, 2607-2615.	1.4	47
71	Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 1961-1968.	5.2	47
72	Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling. <i>Archives of Disease in Childhood</i> , 2014, 99, 267-272.	1.9	46

#	ARTICLE	IF	CITATIONS
73	Predictors of invasive fungal infection in pediatric allogeneic hematopoietic SCT recipients. <i>Bone Marrow Transplantation</i> , 2014, 49, 95-101.	2.4	45
74	Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies. <i>Blood Advances</i> , 2018, 2, 49-60.	5.2	45
75	Metachromatic leukodystrophy and transplantation: remyelination, no cross-correction. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 169-180.	3.7	45
76	Survival in a Recent Cohort of Mechanically Ventilated Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1385-1393.	2.0	44
77	Improvement of White Matter Changes on Neuroimaging Modalities After Stem Cell Transplant in Metachromatic Leukodystrophy. <i>JAMA Neurology</i> , 2013, 70, 779.	9.0	44
78	Nedd4-Binding Protein 1 and TNFAIP3-Interacting Protein 1 Control MHC-1 Display in Neuroblastoma. <i>Cancer Research</i> , 2018, 78, 6621-6631.	0.9	42
79	The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 1118-1128.	5.2	42
80	Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes. <i>Blood Advances</i> , 2019, 3, 2179-2187.	5.2	42
81	Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Pharmacokinetics</i> , 2019, 58, 627-637.	3.5	41
82	Early Umbilical Cord Blood-Derived Stem Cell Transplantation Does Not Prevent Neurological Deterioration in Mucopolysaccharidosis Type III. <i>JIMD Reports</i> , 2014, 18, 63-68.	1.5	40
83	Gallbladder and the risk of polyps and carcinoma in metachromatic leukodystrophy. <i>Neurology</i> , 2016, 87, 103-111.	1.1	40
84	Immune reconstitution and outcomes after conditioning with anti-thymocyte-globulin in unrelated cord blood transplantation; the good, the bad, and the ugly. <i>Stem Cell Investigation</i> , 2017, 4, 38-38.	3.0	40
85	Granulocyte concentrates: prolonged functional capacity during storage in the presence of phenotypic changes. <i>Haematologica</i> , 2008, 93, 1058-1067.	3.5	39
86	GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study. <i>Oncotarget</i> , 2017, 8, 90852-90867.	1.8	39
87	Interferon- γ Protects against Biomaterial-Associated Staphylococcus epidermidis Infection in Mice. <i>Journal of Infectious Diseases</i> , 2000, 181, 1167-1171.	4.0	38
88	Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention. <i>Clinical and Experimental Immunology</i> , 2011, 165, 8-18.	2.6	38
89	Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. <i>Haematologica</i> , 2017, 102, 1291-1298.	3.5	38
90	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. <i>Blood Advances</i> , 2019, 3, 3123-3131.	5.2	37

#	ARTICLE	IF	CITATIONS
91	Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma. <i>Oncotarget</i> , 2015, 6, 35770-35781.	1.8	37
92	Cognate CD4 T-Cell Licensing of Dendritic Cells Heralds Anti-Cytomegalovirus CD8 T-Cell Immunity after Human Allogeneic Umbilical Cord Blood Transplantation. <i>Journal of Virology</i> , 2015, 89, 1058-1069.	3.4	36
93	Subcutaneous abscess formation around catheters induced by viable and nonviable <i>Staphylococcus epidermidis</i> as well as by small amounts of bacterial cell wall components. <i>Journal of Biomedical Materials Research Part B</i> , 2000, 50, 546-556.	3.1	35
94	Pleconaril-resistant chronic parechovirus-associated enteropathy in agammaglobulinaemia. <i>Antiviral Therapy</i> , 2011, 16, 611-614.	1.0	35
95	Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey. <i>Journal of Inherited Metabolic Disease</i> , 2015, 38, 323-331.	3.6	34
96	Antibacterial activity of antibiotic-soaked polyvinylpyrrolidone-grafted silicon elastomer hydrocephalus shunts. <i>Journal of Antimicrobial Chemotherapy</i> , 2000, 45, 221-224.	3.0	32
97	Recurrent and Opportunistic Infections in Children With Primary Intestinal Lymphangiectasia. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2007, 44, 382-385.	1.8	31
98	Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC-MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1055-1056, 81-85.	2.3	31
99	Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. <i>Oncotarget</i> , 2018, 9, 35611-35622.	1.8	31
100	A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome. <i>Haematologica</i> , 2017, 102, 1112-1119.	3.5	30
101	Adenovirus DNA Positivity in Nasopharyngeal Aspirate Preceding Hematopoietic Stem Cell Transplantation: A Very Strong Risk Factor for Adenovirus DNAemia in Pediatric Patients. <i>Clinical Infectious Diseases</i> , 2009, 49, 1536-1539.	5.8	29
102	Neurodevelopmental Outcome after Hematopoietic Cell Transplantation in Inborn Errors of Metabolism: Current Considerations and Future Perspectives. <i>Neuropediatrics</i> , 2016, 47, 285-292.	0.6	29
103	Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies. <i>Cytotherapy</i> , 2020, 22, 474-481.	0.7	29
104	Human herpesvirus 6 viremia affects T-cell reconstitution after allogeneic hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2018, 2, 428-432.	5.2	28
105	Hemorrhagic Cystitis in a Cohort of Pediatric Transplantations: Incidence, Treatment, Outcome, and Risk Factors. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1263-1266.	2.0	27
106	Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1609-1620.	3.5	27
107	Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation. <i>Cytotherapy</i> , 2020, 22, 503-510.	0.7	27
108	CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation. <i>Blood</i> , 2021, 137, 848-855.	1.4	27

#	ARTICLE	IF	CITATIONS
109	Fatal hemophagocytic lymphohistiocytosis in X-linked chronic granulomatous disease associated with a perforin gene variant. <i>Pediatric Blood and Cancer</i> , 2009, 52, 527-529.	1.5	26
110	Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation. <i>Oncolmmunology</i> , 2015, 4, e1023973.	4.6	26
111	Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant. <i>Blood</i> , 2022, 139, 2758-2769.	1.4	25
112	Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial. <i>Lancet Haematology</i> , 2022, 9, e111-e120.	4.6	25
113	Interleukin-1 Receptor Type I Gene-Deficient Mice Are Less Susceptible to Staphylococcus epidermidis Biomaterial-Associated Infection than Are Wild-Type Mice. <i>Infection and Immunity</i> , 2000, 68, 6924-6931.	2.2	24
114	Quantitative MR spectroscopic imaging in metachromatic leukodystrophy: value for prognosis and treatment. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 105-111.	1.9	24
115	Human herpes virus 6 reactivation: important predictor for poor outcome after myeloablative, but not non-myeloablative allo-SCT. <i>Bone Marrow Transplantation</i> , 2013, 48, 1460-1464.	2.4	23
116	Perioperative complications in patients diagnosed with mucopolysaccharidosis and the impact of enzyme replacement therapy followed by hematopoietic stem cell transplantation at early age. <i>Paediatric Anaesthesia</i> , 2014, 24, 521-527.	1.1	23
117	Enhanced Susceptibility to Subcutaneous Abscess Formation and Persistent Infection around Catheters Is Associated with Sustained Interleukin-1 ^β Levels. <i>Infection and Immunity</i> , 2000, 68, 1692-1695.	2.2	21
118	Breastfeeding, atopy, and asthma. <i>Lancet, The</i> , 2003, 361, 174-175.	13.7	21
119	Sufficient Immunosuppression with Thymoglobulin Is Essential for a Successful Haplo-Myeloid Bridge in Haploidentical-Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1839-1845.	2.0	21
120	Advances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disorders. <i>Current Opinion in Pediatrics</i> , 2015, 27, 9-17.	2.0	21
121	Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. <i>Blood Advances</i> , 2018, 2, 1198-1206.	5.2	21
122	Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50 Years or Older with Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 488-495.	2.0	21
123	1 ^β T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies. <i>Blood Advances</i> , 2021, 5, 240-249.	5.2	21
124	Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 72.e1-72.e8.	1.2	21
125	Quality of life of Hurler syndrome patients after successful hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2017, 1, 2236-2242.	5.2	19
126	Filgrastim enhances T-cell clearance by antithymocyte globulin exposure after unrelated cord blood transplantation. <i>Blood Advances</i> , 2018, 2, 565-574.	5.2	19

#	ARTICLE	IF	CITATIONS
127	Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1890-1897.	2.0	19
128	Predicted Indirectly Recognizable HLA Epitopes Class I Promote Antileukemia Responses after Cord Blood Transplantation: Indications for a Potential Novel Donor Selection Tool. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 170-173.	2.0	18
129	Diffusion tensor imaging in metachromatic leukodystrophy. <i>Journal of Neurology</i> , 2018, 265, 659-668.	3.6	18
130	Predictors for Autoimmune Cytopenias after Allogeneic Hematopoietic Cell Transplantation in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 114-122.	2.0	18
131	A semi-mechanistic model based on glutathione depletion to describe intra-individual reduction in busulfan clearance. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1499-1509.	2.4	18
132	The pulmonary metatranscriptome prior to pediatric HCT identifies post-HCT lung injury. <i>Blood</i> , 2021, 137, 1679-1689.	1.4	18
133	Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophy. <i>Brain</i> , 2022, 145, 105-118.	7.6	18
134	Functional and genetic characterization of two extremely rare cases of Williams-Beuren Syndrome associated with chronic granulomatous disease. <i>European Journal of Human Genetics</i> , 2013, 21, 1079-1084.	2.8	17
135	Leukemia-free survival in myeloid leukemia, but not in lymphoid leukemia, is predicted by early CD4+ reconstitution following unrelated cord blood transplantation in children: a multicenter retrospective cohort analysis. <i>Bone Marrow Transplantation</i> , 2016, 51, 1376-1378.	2.4	17
136	Slowly Progressive Psychiatric Symptoms: Think Metachromatic Leukodystrophy. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2018, 57, 74-76.	0.5	17
137	Chromosomally Integrated Human Herpesvirus 6: Transmission via Cord Blood-Derived Unrelated Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 130-132.	2.0	16
138	Viral PCR Positivity in Stool before Allogeneic Hematopoietic Cell Transplantation Is Strongly Associated with Acute Intestinal Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 772-774.	2.0	16
139	Infection with a respiratory virus before hematopoietic cell transplantation is associated with alloimmune-mediated lung syndromes. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 697-703.e8.	2.9	16
140	Cord-Blood-Stem-Cell-Derived Conventional Dendritic Cells Specifically Originate from CD115-Expressing Precursors. <i>Cancers</i> , 2019, 11, 181.	3.7	16
141	Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, 337-340.	1.3	16
142	Ocular Complications in Children Within 1 Year After Hematopoietic Stem Cell Transplantation. <i>JAMA Ophthalmology</i> , 2013, 131, 470.	2.5	15
143	A novel Fc γ R1a Q27W gene variant is associated with common variable immune deficiency through defective Fc γ R1a downstream signaling. <i>Clinical Immunology</i> , 2014, 155, 108-117.	3.2	15
144	Challenges in the harmonization of immune monitoring studies and trial design for cell-based therapies in the context of hematopoietic cell transplantation for pediatric cancer patients. <i>Cytotherapy</i> , 2015, 17, 1667-1674.	0.7	15

#	ARTICLE	IF	CITATIONS
145	Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1526-1535.	2.0	15
146	A dominant activating RAC2 variant associated with immunodeficiency and pulmonary disease. <i>Clinical Immunology</i> , 2020, 212, 108248.	3.2	15
147	Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1149-1155.	2.3	14
148	Practice pattern changes and improvements in hematopoietic cell transplantation for primary immunodeficiencies. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 2004-2007.	2.9	14
149	Innate Immune Recovery Predicts CD4+ T Cell Reconstitution after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 819-826.	2.0	14
150	Durable Remission Following "Off-the-Shelf" Chimeric Antigen Receptor (CAR) T-Cells in Patients with Relapse/Refractory (R/R) B-Cell Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S89.	2.0	13
151	First analysis of human herpesvirus 6 T-cell responses: Specific boosting after HHV6 reactivation in stem cell transplantation recipients. <i>Clinical Immunology</i> , 2012, 144, 179-189.	3.2	12
152	Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control?. <i>Frontiers in Immunology</i> , 2014, 5, 218.	4.8	12
153	Individualized conditioning regimes in cord blood transplantation: Towards improved and predictable safety and efficacy. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 801-813.	3.1	12
154	Epstein-Barr virus lymphoproliferative disease after solid organ transplantation. <i>Cytotherapy</i> , 2017, 19, 1270-1283.	0.7	12
155	Immune Monitoring during Therapy Reveals Activatory and Regulatory Immune Responses in High-Risk Neuroblastoma. <i>Cancers</i> , 2021, 13, 2096.	3.7	12
156	Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2022, 6, 1054-1063.	5.2	12
157	Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Venous-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 196-202.	1.2	12
158	Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 530-545.	1.2	12
159	Pre-emptive granulocyte transfusions enable allogeneic hematopoietic stem cell transplantation in pediatric patients with chronic infections. <i>Bone Marrow Transplantation</i> , 2006, 37, 331-333.	2.4	11
160	Changing winds in refractory autoimmune disease in children. <i>Current Opinion in Rheumatology</i> , 2012, 24, 267-273.	4.3	11
161	Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP. <i>Bone Marrow Transplantation</i> , 2015, 50, 592-597.	2.4	11
162	In vivo and in vitro palatability testing of a new paediatric formulation of valaciclovir. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2789-2797.	2.4	11

#	ARTICLE	IF	CITATIONS
163	Strategies to Genetically Modulate Dendritic Cells to Potentiate Anti-Tumor Responses in Hematologic Malignancies. <i>Frontiers in Immunology</i> , 2018, 9, 982.	4.8	11
164	Bone-marrow derived mesenchymal stromal cells infusion in therapy refractory juvenile idiopathic arthritis patients. <i>Rheumatology</i> , 2019, 58, 1812-1817.	1.9	11
165	Genetic Susceptibility to Hepatic Sinusoidal Obstruction Syndrome in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 920-927.	2.0	11
166	Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant. <i>Bone Marrow Transplantation</i> , 2020, 55, 2160-2169.	2.4	11
167	Variables affecting outcomes after allogeneic hematopoietic stem cell transplant for cerebral adrenoleukodystrophy. <i>Blood Advances</i> , 2022, 6, 1512-1524.	5.2	11
168	Fine-Tuning Antithymocyte Globulin Dosing and Harmonizing Clinical Trial Design. <i>Journal of Clinical Oncology</i> , 2018, 36, 1175-1176.	1.6	10
169	Morbidity and Mortality Associated With Respiratory Virus Infections in Allogeneic Hematopoietic Cell Transplant: Too Little Defense or Harmful Immunity?. <i>Frontiers in Microbiology</i> , 2018, 9, 2795.	3.5	10
170	Risk factors affecting outcome of unrelated cord blood transplantation for children with familial haemophagocytic lymphohistiocytosis. <i>British Journal of Haematology</i> , 2019, 184, 397-404.	2.5	10
171	Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for Metachromatic Leukodystrophy: The European Metachromatic Leukodystrophy initiative (MLDi). <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 48.	2.7	10
172	Bone-marrow transplantation in non-malignant disease. <i>Lancet, The</i> , 2009, 374, 856-858.	13.7	9
173	Life-threatening human herpes virus-6 infection in early childhood: Presenting symptom of a primary immunodeficiency?. <i>Pediatric Critical Care Medicine</i> , 2009, 10, e16-e18.	0.5	9
174	Population Pharmacokinetic Modeling of Thymoglobulin in Children Receiving Allogeneic-Hematopoietic Cell Transplantation (HCT): Towards Individualized Dosing to Improve Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S96-S98.	2.0	9
175	High Diagnostic Yield of Dedicated Pulmonary Screening before Hematopoietic Cell Transplantation in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1622-1626.	2.0	9
176	Postâ€hematopoietic stem cell transplant hemophagocytic lymphohistiocytosis or an impostor: Case report and review of literature. <i>Pediatric Transplantation</i> , 2018, 22, e13174.	1.0	9
177	Solid organ transplantation after hematopoietic stem cell transplantation in childhood: A multicentric retrospective survey. <i>American Journal of Transplantation</i> , 2019, 19, 1798-1805.	4.7	9
178	Allogeneic Haematopoietic Cell Transplantation for Epidermolysis Bullosa: the Dutch Experience. <i>Acta Dermato-Venereologica</i> , 2019, 99, 347-348.	1.3	9
179	Clinical Grade Production of Wilmsâ€™ Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 559152.	4.8	9
180	Metachromatic leukodystrophy genotypes in The Netherlands reveal novel pathogenic ARSA variants in non-Caucasian patients. <i>Neurogenetics</i> , 2020, 21, 289-299.	1.4	9

#	ARTICLE	IF	CITATIONS
181	Efficacy of MSC for steroid-refractory acute GVHD associates with MSC donor age and a defined molecular profile. <i>Bone Marrow Transplantation</i> , 2020, 55, 2188-2192.	2.4	9
182	Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders. <i>Bone Marrow Transplantation</i> , 2021, 56, 1238-1247.	2.4	9
183	Therapeutic Drug Monitoring of Anti-Thymocyte Globulin in Allogeneic Stem Cell Transplantation: Proof of Concept. <i>Frontiers in Pharmacology</i> , 2022, 13, 828094.	3.5	9
184	Curative therapy for hemoglobinopathies: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo stem cell gene therapy versus allogeneic hematopoietic stem cell transplantation. <i>Cytotherapy</i> , 2022, 24, 249-261.	0.7	9
185	Epstein-Barr virus-associated haemophagocytic lympho-histiocytosis after stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2006, 38, 709-710.	2.4	8
186	Will Post-Transplantation Cell Therapies for Pediatric Patients Become Standard of Care?. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 402-411.	2.0	8
187	Immune Monitoring After Allogeneic Hematopoietic Cell Transplantation: Toward Practical Guidelines and Standardization. <i>Frontiers in Pediatrics</i> , 2020, 8, 454.	1.9	8
188	Hurdles in treating Hurler disease: potential routes to achieve a "real" cure. <i>Blood Advances</i> , 2020, 4, 2837-2849.	5.2	8
189	A Minimal Parameter Set Facilitating Early Decision-making in the Diagnosis of Hemophagocytic Lymphohistiocytosis. <i>Journal of Clinical Immunology</i> , 2021, 41, 1219-1228.	3.8	8
190	Nicord Single Unit Expanded Umbilical Cord Blood Transplantation: Final Results of a Multicenter Phase I/ II Trial. <i>Blood</i> , 2017, 130, 847-847.	1.4	8
191	Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen. <i>Blood Advances</i> , 2022, 6, 1719-1730.	5.2	8
192	Successful cord blood transplantation in a premature and dysmature neonate of 1700g with reticular dysgenesis. <i>Bone Marrow Transplantation</i> , 2007, 39, 307-308.	2.4	7
193	A novel Dutch mutation in <i>UNC13D</i> reveals an essential role of the C2B domain in munc13-4 function. <i>Pediatric Blood and Cancer</i> , 2012, 58, 598-605.	1.5	7
194	Multi-Institutional Assessments of Transplantation for Metabolic Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S58-S63.	2.0	7
195	Increased proportion of perforin-expressing CD8+T-cells indicates control of herpesvirus reactivation in children after stem cell transplantation. <i>Clinical Immunology</i> , 2013, 148, 92-98.	3.2	7
196	Prospective Open-Label Phase II Trial of Individualized Anti-Thymocyte Globulin for Improved T-Cell Reconstitution after Pediatric Allogeneic Hematopoietic Cell Transplantation: The Parachute-Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S33-S34.	2.0	7
197	Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens. <i>Bone Marrow Transplantation</i> , 2021, 56, 1426-1432.	2.4	7
198	Outcomes in Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia. <i>Transplantation and Cellular Therapy</i> , 2021, 28, 101.e1-101.e1.	1.2	7

#	ARTICLE	IF	CITATIONS
199	Outcomes of transplantation of unrelated cord blood in children with malignant and non-malignant diseases: an Utrecht-Prague collaborative study. <i>Bone Marrow Transplantation</i> , 2009, 43, 655-657.	2.4	6
200	Does high-resolution CT has diagnostic value in patients presenting with respiratory symptoms after hematopoietic stem cell transplantation?. <i>European Journal of Radiology</i> , 2011, 80, e536-e543.	2.6	6
201	Familial Hemophagocytic Lymphohistiocytosis in a Pediatric Patient Diagnosed by Brain Magnetic Resonance Imaging. <i>Neuropediatrics</i> , 2011, 42, 191-193.	0.6	6
202	Longitudinal Analysis of Ocular Disease in Children with Mucopolysaccharidosis I after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 928-935.	2.0	6
203	Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 272-281.	2.5	6
204	Outcome After Cord Blood Transplantation Using Busulfan Pharmacokinetics-Targeted Myeloablative Conditioning for Hurler Syndrome. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 91.e1-91.e4.	1.2	6
205	Efficient lentiviral transduction method to gene modify cord blood CD8+ T cells for cancer therapy applications. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 357-368.	4.1	6
206	Donor-Host Lineage-Specific Chimerism Monitoring and Analysis in Pediatric Patients Following Allogeneic Stem Cell Transplantation: Influence of Pretransplantation Variables and Correlation with Post-Transplantation Outcomes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 780.e1-780.e14.	1.2	6
207	Pulmonary microbiome and gene expression signatures differentiate lung function in pediatric hematopoietic cell transplant candidates. <i>Science Translational Medicine</i> , 2022, 14, eabm8646.	12.4	6
208	Stem cell source-dependent reconstitution of FOXP3+ T cells after pediatric SCT and the association with allo-reactive disease. <i>Bone Marrow Transplantation</i> , 2013, 48, 502-507.	2.4	5
209	The power of cord blood cells. <i>Blood</i> , 2016, 127, 3302-3303.	1.4	5
210	Use of cord blood derived T-cells in cancer immunotherapy: milestones achieved and future perspectives. <i>Expert Review of Hematology</i> , 2018, 11, 209-218.	2.2	5
211	Hearing loss in patients with mucopolysaccharidoses α 1 and α 6 after hematopoietic cell transplantation: A longitudinal analysis. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 1279-1287.	3.6	5
212	Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2826-2833.	2.4	5
213	B-cell depletion abrogates immune mediated cytopenia and rejection of cord blood transplantation in Hurler syndrome. <i>Bone Marrow Transplantation</i> , 2022, 57, 38-42.	2.4	5
214	Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing Regimens. <i>Clinical Pharmacokinetics</i> , 2022, 61, 553-563.	3.5	5
215	Dried Blood Spot Analysis: An Easy and Reliable Tool to Monitor the Biochemical Effect of Hematopoietic Stem Cell Transplantation in Hurler Syndrome Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 701-704.	2.0	4
216	Evaluation of effects of busulfan and DMA on SOS in pediatric stem cell recipients. <i>Pediatric Blood and Cancer</i> , 2014, 61, 306-311.	1.5	4

#	ARTICLE	IF	CITATIONS
217	Stem cell comparison: what can we learn clinically from unrelated cord blood transplantation as an alternative stem cell source?. <i>Cytotherapy</i> , 2015, 17, 695-701.	0.7	4
218	Incomplete biomarker response in mucopolysaccharidosis type I after successful hematopoietic cell transplantation. <i>Molecular Genetics and Metabolism</i> , 2017, 122, 86-91.	1.1	4
219	Antithymocyte Globulin: Steps Toward Individualized Dosing. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 633-634.	2.0	4
220	Anti-thymocyte globulin for GVHD: one dose does not fit all. <i>Lancet Haematology</i> , 2020, 7, e505.	4.6	4
221	Early CD4+ T Cell Reconstruction As Predictor for Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric and Young Adult Patients: A Validation Cohort Analyses. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S302-S303.	2.0	4
222	Population pharmacokinetics of clofarabine for allogeneic hematopoietic cell transplantation in paediatric patients. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3218-3226.	2.4	4
223	GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	2.5	4
224	Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 993.e1-993.e8.	1.2	4
225	Umbilical cord blood: advances and opportunities. <i>Cytotherapy</i> , 2015, 17, 693-694.	0.7	3
226	Antithymocyte globulin: Importance of good clinical pharmacological practice. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 633.	2.9	3
227	Busulfan after HSCT in children and young adults – Authors' reply. <i>Lancet Haematology</i> , 2017, 4, e103-e104.	4.6	3
228	Salivary Î±-Iduronidase Activity as a Potential New Biomarker for the Diagnosis and Monitoring the Effect of Therapy in Mucopolysaccharidosis Type I. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1808-1813.	2.0	3
229	A “No-Touch” Antibody Staining Method of Adherent Cells for High-Throughput Flow Cytometry in 384-Well Microplate Format for Cell-Based Drug Library Screening. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 845-851.	1.5	3
230	New insights in phenotype and treatment of lung disease immuno-deficiency and chromosome breakage syndrome (LICS). <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 137.	2.7	3
231	Defibrotide (DF) for the Prevention of Hepatic Veno-Occlusive Disease (VOD) in Pediatric Stem Cell Transplantation: Results of a Prospective Phase II/III Randomized, Multicenter Study.. <i>Blood</i> , 2009, 114, 653-653.	1.4	3
232	Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 679-679.	1.4	3
233	NiCord single unit expanded umbilical cord blood transplantation: Results of phase I/II trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7004-7004.	1.6	3
234	Impact Of Prophylaxis With Defibrotide On The Occurrence Of Acute GvHD In Allogeneic HSCT. <i>Blood</i> , 2013, 122, 4591-4591.	1.4	3

#	ARTICLE	IF	CITATIONS
235	Viral infection in hematopoietic stem cell transplantation: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review on the role of cellular therapy in prevention and treatment. <i>Cytotherapy</i> , 2022, 24, 884-891.	0.7	3
236	X-ALD: centralize care in an international network. <i>Blood</i> , 2011, 118, 1716-1717.	1.4	2
237	Exposure of Thymoglobulin Is Associated with Overall Survival in Children Receiving Allogeneic-Hematopoietic Cell Transplantation (HCT): Towards Individualized Dosing to Improve Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S76-S78.	2.0	2
238	Combining Clofarabine and Fludarabine with Exposure Targeted Busulfan for Pediatric Leukemia: An Effective, Low Toxicity TBI-Free Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S99-S100.	2.0	2
239	High Exposure to Fludarabine in Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation Predicts for Impaired CD4 Reconstitution and Lower Survival Chances. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S72-S73.	2.0	2
240	Rapid and Robust CD4+ and CD8+ T-, NK-, B-Cell, Dendritic Cell, and Monocyte Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S55.	2.0	2
241	Conditioning Prior to CAR T Cells Predicts Response and Survival in Pediatric/Young Adult Relapse/Refractory (R/R) B-ALL. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S170.	2.0	2
242	Early CD4+ T-Cell Reconstitution Is an Excellent Predictor for Survival and Non-Relapse Mortality in Pediatric and Young Adult Patients Who Develop Moderate to Severe Acute Graft-Versus-Host-Disease; A Dual Center Validation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S188-S189.	2.0	2
243	Genetic susceptibility to acute graft versus host disease in pediatric patients undergoing HSCT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2697-2704.	2.4	2
244	Long-term effect of hematopoietic cell transplantation on systemic inflammation in patients with mucopolysaccharidoses. <i>Blood Advances</i> , 2021, 5, 3092-3101.	5.2	2
245	Results of Haematopoietic Stem Cell Transplantation (HSCT) for Hurler's Syndrome: European Experience 1994-2004. <i>Blood</i> , 2005, 106, 402-402.	1.4	2
246	Defibrotide for the Treatment of Veno-Occlusive Disease Post SCT: Preliminary Results of EU Compassionate Use Program in 332 Patients Confirm Promising Activity and Manageable Toxicity. <i>Blood</i> , 2007, 110, 613-613.	1.4	2
247	The Impact Of Thymoglobulin Prior To Pediatric Unrelated Umbilical Cord Blood Transplantation On Immune-Reconstitution and Clinical Outcome. <i>Blood</i> , 2013, 122, 3305-3305.	1.4	2
248	The in vitro Antimicrobial Activity of PVP-grafted Versus Conventional Silicon Elastomer CSF-shunts. <i>Neurosurgery</i> , 1997, 41, 736.	1.1	2
249	Clinical and Biological Concepts for Mastering Immune Reconstitution After HSCT: Toward Practical Guidelines and Greater Harmonization. , 2019, , 69-74.		2
250	Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients. <i>Cytotherapy</i> , 2022, 24, 428-436.	0.7	2
251	An ISCT Stem Cell Engineering Committee Position Statement on Immune Reconstitution: the importance of predictable and modifiable milestones of immune reconstitution to transplant outcomes. <i>Cytotherapy</i> , 2022, 24, 385-392.	0.7	2
252	EBV post transplantation lymphoproliferative disease-associated pneumomediastinum in a pediatric patient with long-lasting low loads of plasma EBV-DNA positivity. <i>Bone Marrow Transplantation</i> , 2008, 42, 565-566.	2.4	1

#	ARTICLE	IF	CITATIONS
253	Adenovirus PCR-Positivity in Stool Precedes Intestinal GRAFT Versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S318.	2.0	1
254	High-Resolution CT Can Differentiate Between Alloimmune and Nonalloimmune Lung Disease Early After Hematopoietic Cell Transplantation. <i>American Journal of Roentgenology</i> , 2014, 203, 656-661.	2.2	1
255	Variable Success Rates of Haplo-Cord Transplants in High Risk Patients: A Minimum Serotherapy Exposure Is a Prerequisite for Sustainable Engrafting. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S239-S240.	2.0	1
256	Haematopoietic Cell Transplant (HCT) in Pediatric Acute Myeloid Leukemia (AML) after Similar Upfront Therapy with AML-Nopho; a Comparison of Conditioning Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S138-S139.	2.0	1
257	Individualized Dosing and Therapeutic Drug Monitoring (TDM) of ATG is Feasible, Safe, Effective, and Associated with Excellent Immune Reconstitution. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S124-S125.	2.0	1
258	Rabbit anti-human-T-lymphocyte globulinâ€”less is more. <i>Lancet Oncology</i> , The, 2017, 18, 996-997.	10.7	1
259	Individualized Fludarabine Dosing for Predictable Immune Reconstitution and Increased Survival Chances after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S306-S307.	2.0	1
260	How to define and measure thymopoiesis after transplantation?. <i>Bone Marrow Transplantation</i> , 2018, 53, 1364-1365.	2.4	1
261	Pharmacotherapy in Pediatric Hematopoietic Cell Transplantation. <i>Handbook of Experimental Pharmacology</i> , 2019, 261, 471-489.	1.8	1
262	Tyrosine kinase inhibitor levels matter in treating chronic GVHD. <i>Bone Marrow Transplantation</i> , 2019, 54, 1141-1144.	2.4	1
263	Population Pharmacokinetic Model Demonstrates Poor Outcomes with ATG Overexposure in Adults Undergoing Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S157.	2.0	1
264	Therapy-type related long-term outcomes in mucopolysaccharidosis type II (Hunter syndrome) â€” Case series. <i>Molecular Genetics and Metabolism Reports</i> , 2021, 28, 100779.	1.1	1
265	Related and Unrelated Donor Transplantation for β^2 Thalassemia Major: Results of an International Survey. <i>Blood</i> , 2018, 132, 308-308.	1.4	1
266	Risk Factor Analysis of Outcomes after Unrelated Cord Blood Transplantation for Children with Hurlerâ€™s Syndrome. An Eurocord-Duke University Collaborative Study.. <i>Blood</i> , 2007, 110, 5076-5076.	1.4	1
267	Safety and Efficacy of Enzyme Replacement Therapy (ERT) in Combination with Haematopoietic Stem Cell Transplantation (HSCT) for Hurlerâ€™s Syndrome: European Experience 2003â€”2005.. <i>Blood</i> , 2005, 106, 5307-5307.	1.4	1
268	Comparison of Outcomes for Myeloablative Conditioning Regimens Combining Busulfan with Either Cyclophosphamide or Fludarabine in Children. <i>Blood</i> , 2016, 128, 664-664.	1.4	1
269	Timing of Induction Treatment for Reactivation of Cytomegalovirus Impacts Overall Survival in Pediatric Allogeneic Hematopoietic Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S347.	2.0	1
270	Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation. <i>Pharmacogenomics Journal</i> , 2022, 22, 9-18.	2.0	1

#	ARTICLE	IF	CITATIONS
271	130-P. Human Immunology, 2006, 67, S136.	2.4	0
272	298 Cd3+Cd4+-Lymphocytes as Biomarker Predicting the Outcome of Pediatric Haematopoietic Stem Cell Transplantation Recipients. Pediatric Research, 2010, 68, 153-153.	2.3	0
273	50-OR. Human Immunology, 2013, 74, 39.	2.4	0
274	Treatment of Steroid Resistant Grade II to IV Acute GVHD by Infusion of Mesenchymal Stroma Cells Expanded with Platelet Lysate - a Phase I/II Study. Biology of Blood and Marrow Transplantation, 2013, 19, S144.	2.0	0
275	Development of a unique anti-AML immune therapy consisting of cord blood HSCT and cord blood stem cell-derived dendritic cell (CB-DC) vaccination. , 2013, 1, .		0
276	Fludarabine in paediatric steroid-refractory inflammatory lung injury after stem cell transplantation. European Respiratory Journal, 2013, 41, 479-483.	6.7	0
277	HSCT for inborn errors of metabolism and neurodegenerative disorders. , 0, , 192-204.		0
278	Prospective Validation of a Busulfan Pharmacokinetic Model in Children: Therapeutic Drug Monitoring Remains of Utmost Importance to Optimize Outcomes of HCT. Biology of Blood and Marrow Transplantation, 2014, 20, S248.	2.0	0
279	Development of a Unique Anti-AML Immune Therapy Consisting of Cord Blood HSCT and Cord Blood Stem Cell-Derived Dendritic Cell (CB-DC) Vaccination. Biology of Blood and Marrow Transplantation, 2014, 20, S133.	2.0	0
280	Predictors of Long-Term Clinical Outcome in Hurler Syndrome Patients after Successful Hematopoietic Cell Transplantation: An International Study. Biology of Blood and Marrow Transplantation, 2014, 20, S78-S79.	2.0	0
281	Outcomes of Allogeneic Cord Blood Transplantation for Leukodystrophies; A Joint Study of Eurocord and "Inborn Errors WP-EBMT". Biology of Blood and Marrow Transplantation, 2014, 20, S86-S87.	2.0	0
282	Predicted Indirectly Recognizable Hla Epitopes (PIRCHE) Provide a Novel Strategy to Individualize Donor Selection That Optimizes Survival Chances. Biology of Blood and Marrow Transplantation, 2015, 21, S350-S351.	2.0	0
283	Health-Related Quality of Life and Perception of Care of Mucopolysaccharidosis Type I - Hurler Syndrome Patients after Successful Hematopoietic Cell Transplantation: A Parents' Perspective. Biology of Blood and Marrow Transplantation, 2015, 21, S207-S208.	2.0	0
284	Upregulation of Class I MHC on Neuroblastoma Cells By NK Cell Exposure for Enhanced CTL Reactivity. Biology of Blood and Marrow Transplantation, 2015, 21, S240.	2.0	0
285	Respiratory Virus (RV) from Broncho Alveolar Lavage (BAL) Prior to Hematopoietic Cell Transplantation (HCT): A Strong Predictor for Allo-Immune Mediated Lung Syndromes (allo-LS). Biology of Blood and Marrow Transplantation, 2015, 21, S54-S55.	2.0	0
286	Thymoglobulin® Exposure Is Influencing CD4+ Immune Reconstitution As a Predictor for Improved Overall Survival in Pediatric Haematopoietic Cell Transplantation: Towards Individualized Dosing. Biology of Blood and Marrow Transplantation, 2015, 21, S91-S92.	2.0	0
287	Upregulation of class I MHC on neuroblastoma cells by NK cell exposure for enhanced CTL reactivity. Cytotherapy, 2015, 17, S19.	0.7	0
288	Preclinical development of cord blood-derived dendritic cell-based immunotherapies after hematopoietic cell transplantation in children with AML. Cytotherapy, 2015, 17, S9.	0.7	0

#	ARTICLE	IF	CITATIONS
289	CD4+ Reconstitution and Event Free Survival Are Predicted By Low ATG Exposure after Cord Blood Transplantation in Children: Towards Individualized ATG Dosing to Improve Survival Chances. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S97-S98.	2.0	0
290	CD4+ T-Cell Reconstitution Strongly Predicts Viral Reactivations Associated with Complications and Mortality after Pediatric Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S300.	2.0	0
291	Cord Blood Transplantation in Chemotherapy Na ⁺ ve Patients Predisposes for Autoimmune Cytopenia in Pediatric Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S252-S253.	2.0	0
292	Innate Immune Subset Recovery is Superior after Cord Blood Compared to Bone Marrow in Pediatric Hematopoietic Cell Transplantation and Relates to Superior Survival Chances. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S164-S165.	2.0	0
293	Optimizing Anti-Thymocyte Globulin Exposure to Improve Survival Chances after Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S45-S46.	2.0	0
294	Nicord Single Unit Expanded Umbilical Cord Blood Transplantation (UCBT): Final Results of a Multicenter Phase I/ II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S57.	2.0	0
295	The Influence of Stem Cell Source on Chronic-GvHD Free, Leukemia Free Transplant Survival in Pediatric Patients with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S113-S114.	2.0	0
296	Quality of Life of Hurler Syndrome Patients after Successful Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S29-S30.	2.0	0
297	G-CSF Treatment Further Impairs T-Cell Reconstitution in Patients with Residual Anti-Thymocyte Globulin Exposure after Hematopoietic Cell Transplantation: Implications for G-CSF Use?. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S37.	2.0	0
298	Relating Autoimmune Cytopenias after Hematopoietic Cell Transplantation (HCT) to Transplant-Variables and Immune Reconstitution: A Predictor Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S183-S184.	2.0	0
299	Relating Alloimmune-Mediated Lung Complications after Hematopoietic Cell Transplantation (HCT) to Immune Reconstitution after HCT to Identify Early Predictors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S184.	2.0	0
300	Excellent Survival Chances after Pharmacokinetic-Targeted Busulfan Plus Fludarabine and ATG for Children with Hurler Syndrome Undergoing Unrelated Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S117.	2.0	0
301	Metatranscriptomic Evaluation of Pulmonary Complications after Pediatric Hematopoietic Cell Transplantation Reveals Pathogenic Microbes Linked to Dysregulated Human Immunologic Gene Expression. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S45.	2.0	0
302	Predictors of Donor/Host (D/H) Lineage Specific Chimerism Trends in Pediatric Patients Following Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S219.	2.0	0
303	Adequate CD4+ T Cell Reconstitution Prior to Onset of Agvhd Grade II-IV Protects Against Transplantation Related Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S227-S228.	2.0	0
304	Longitudinal Analysis of the Effect of Hematopoietic Cell Transplantation on Ocular Disease in Children with Mucopolysaccharidosis I Shows Ongoing Disease Progression. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S41-S42.	2.0	0
305	Retrospective Review of Use of Individualized Dosing of Rabbit Anti-Thymocyte Globulin on Outcomes in Pediatric Post Allogeneic Stem Cell Transplant Patients: A Single Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S196-S197.	2.0	0
306	Outcomes of Allogeneic Hematopoietic Stem Cell Transplant in Patients with Cerebral Adrenoleukodystrophy (CALD): Results from an Ongoing, Large, Multicenter, Observational Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S312.	2.0	0

#	ARTICLE	IF	CITATIONS
307	Combined haploidentical and umbilical cord blood transplantation for severe aplastic anemia: Unique hematopoietic reconstitution. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2019, 12, 119-123.	0.9	0
308	Transplant- and Disease-Related Outcomes of Allogeneic Hematopoietic Stem Cell Transplant in Patients with Cerebral Adrenoleukodystrophy Vary By Donor Cell Source, Conditioning Regimen, and Stage of Cerebral Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S211.	2.0	0
309	Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e235-e236.	2.0	0
310	Towards new long-term composite "Quality of Survival"™ endpoints. <i>Bone Marrow Transplantation</i> , 2020, 55, 1898-1899.	2.4	0
311	Time-Driven Activity-Based Costing (TDBAC) Identifies Time and Effort Required for Completion of CIBMTR Forms and Can Assist in Resource Planning for HCT Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S254.	2.0	0
312	Rabbit Anti-Thymocyte Globulin (ATG) Exposure after Ex Vivo T-Cell Depleted Hematopoietic Cell Transplantation Is Highly Variable and Impacts Immune Reconstitution in Pediatric and Young Adult Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S155.	2.0	0
313	Combining Clofarabine/Fludarabine with Exposure Targeted Busulfan for Pediatric Leukemia Is an Effective, Low Toxic TBI-Free Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S34.	2.0	0
314	Harmonization, biomarkers, disease risk index. <i>Blood</i> , 2021, 137, 874-875.	1.4	0
315	Persistent or New Cytopenias Are a Better Predictor of Relapse Than Routine Bone Marrow Aspirate Evaluations after Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome in Pediatric and Young Adult Patients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, S137-S139.	1.2	0
316	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Cerebral Adrenoleukodystrophy: Effects of Donor Cell Source and Match, Conditioning Regimen, and Stage of Cerebral Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, S318-S319.	1.2	0
317	Pre-Emptive Granulocyte Transfusions (GTx) in Pediatric Patients with a Chronic Bacterial or Fungal Infection Undergoing a Hematopoietic Stem Cell Transplantation (HSCT).. <i>Blood</i> , 2005, 106, 5340-5340.	1.4	0
318	Incidence of Venous Occlusive Disease with IV in Busulfan Children Is Higher Than Expected: Preliminary Results of the VOD-DF Trial.. <i>Blood</i> , 2009, 114, 3344-3344.	1.4	0
319	Treatment of Steroid Resistant Grade II to IV Acute Gvhd by Infusion of Mesenchymal Stroma Cells Expanded with Human Plasma and Platelet Lysate - a Phase I/II Study. <i>Blood</i> , 2011, 118, 3046-3046.	1.4	0
320	Long Term Outcomes of Hematopoietic Stem Cell Transplantation in Patients with Severe Phenotype Hurler Syndrome: an International Multi-Center Study. <i>Blood</i> , 2012, 120, 1958-1958.	1.4	0
321	Treatment of Steroid Resistant Grade II to IV Acute Gvhd by Infusion of Mesenchymal Stroma Cells Expanded with Human Plasma and Platelet Lysate - a Phase I/II Study. <i>Blood</i> , 2012, 120, 736-736.	1.4	0
322	Concluding Comments and Future Directions. <i>Pancreatic Islet Biology</i> , 2013, , 159-166.	0.3	0
323	Hematopoietic Cell Transplantation in Inborn Errors of Metabolism. <i>Pancreatic Islet Biology</i> , 2013, , 37-61.	0.3	0
324	Outcomes Of Allogeneic Cord Blood Transplantation For Leukodystrophies; A Joint Study of Eurocord and "Inborn Errors WP-EBMT". <i>Blood</i> , 2013, 122, 2101-2101.	1.4	0

#	ARTICLE	IF	CITATIONS
325	The in vitro Antimicrobial Activity of PVP-grafted Versus Conventional Silicon Elastomer CSF-shunts. <i>Neurosurgery</i> , 1997, 41, 736-736.	1.1	0
326	Genetic Determinants of Busulfan Clearance and Outcomes in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation- Result of a Multicentric Prospective Study on Behalf of the Pediatric Disease Working Party of the European Blood and Marrow Transplantation Group. <i>Blood</i> , 2014, 124, 424-424.	1.4	0
327	Functional GSTA1 Haplotypes Affect Clearance and Toxicity of Busulfan When Administered in 16 Doses to Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Multicenter Prospective Study on Behalf of the Pediatric Disease Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 665-665.	1.4	0
328	Contemporary Conditioning Regimen before Allogeneic Stem Cell Transplantation for Children with Non-Malignant Diseases. <i>Blood</i> , 2016, 128, 3398-3398.	1.4	0
329	Results of phase 1 clinical trial evaluating efficacy of 3rd party cord blood regulatory T cells for prevention of graft versus host disease.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15047-e15047.	1.6	0
330	First Results of a Prospective I/II Clinical Trial in Adult Patients Using TCR Alpha/Beta Depleted Stem Cell Transplantation from Matched Related and Unrelated Donors. <i>Blood</i> , 2018, 132, 2164-2164.	1.4	0
331	Rapid and Robust CD4+ and CD8+ T-, NK-, B- and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation. <i>Blood</i> , 2018, 132, 2123-2123.	1.4	0
332	Pediatric primary pleural synovial sarcoma: A unique case report with brief review of literature. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2019, 40, 435.	0.2	0
333	Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALL. <i>Blood</i> , 2019, 134, 4582-4582.	1.4	0
334	Towards individualized, low toxic conditioning in autologous gene-transduced hematopoietic cell transplantation. <i>Cell & Gene Therapy Insights</i> , 2019, 5, 1495-1503.	0.1	0
335	Comparison of Fixed Vs ALC-Based Doses of Thymoglobulin [®] (ATG) in Pediatric Patients with Acute Leukemia Given \pm haplo-HSCT: Impact on Immune Reconstitution at Day 90. <i>Blood</i> , 2020, 136, 16-16.	1.4	0
336	Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults. <i>Blood</i> , 2020, 136, 30-31.	1.4	0
337	Encouraging Outcomes after Unrelated Cord Blood Grafts for Post-Transplant Relapse in Pediatric Patients. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S434-S435.	1.2	0